# VERACYTE, INC. (VCYT) · Edgar & Edgarette company card

> Veracyte (VCYT) grew revenue 16.0% in FY2025 to $517 million, operating margin 11.2% against a -12.4% median for medical laboratories, equity 93.1% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1384101 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/VCYT) · [JSON](https://www.pops4.com/boards/company/VCYT.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $517M |
| Revenue growth, 1 year | 16.0% |
| Revenue growth per year | 23.9% |
| Operating margin | 11.2% (prior year 3.6%) |
| Net margin | 12.8% |
| Operating cash flow | $136M |
| Capital spending | $10M |
| Free cash flow | $127M |
| Cash | $363M |
| Long-term debt | — |
| Total assets | $1.4B |
| Total equity | $1.3B |
| Equity ÷ assets | 93.1% |
| Return on equity | 5.1% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: 15.66 (safe zone)
- Piotroski F: 8 of 9 (strong)
- Health Harbor boat: New ship · no warning signs
- Cash Compass: Cash cow later · growing fast, and already turning revenue into cash

## Edgarette's reading

Exposure: revenue $517.1M (FY2025). Experience: revenue up 16.0% on the year, up 23.9% a year over 4 years; operating margin 11.2%, up from 3.6%. Soundness: equity 93.1% of assets, return on equity 5.1%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $521.0M and $688.6M next year (method v4.1: its own 4-year record of growth weighed at 50% against $100M–1B filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $485.5M to $741.1M. A statistical range, not company guidance. Against peers (17 filers, $50M+ revenue, services-medical laboratories): operating margin 11.2% against a -12.4% median; growth 16.0% against 13.8%.

Range logged 2026-10-09, receipt 254b333c1876fd0f, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 2, latest 2026-06-11 ([filing](https://www.sec.gov/Archives/edgar/data/1384101/000138410126000038/0001384101-26-000038-index.htm))

## Recent filings

- 8-K · filed 2026-09-14 · 1.01 Entry into a Material Definitive Agreement; 2.01 Completion of Acquisition or Disposition of Assets; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1384101/000138410126000049/0001384101-26-000049-index.htm)
- 10-Q · filed 2026-07-31 · [filing](https://www.sec.gov/Archives/edgar/data/1384101/000138410126000044/0001384101-26-000044-index.htm)
- 8-K · filed 2026-07-30 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1384101/000138410126000042/0001384101-26-000042-index.htm)
- 8-K · filed 2026-06-11 · 5.02 Departure or Election of Directors; Appointment of Officers; 5.07 Submission of Matters to a Vote of Security Holders · [filing](https://www.sec.gov/Archives/edgar/data/1384101/000138410126000038/0001384101-26-000038-index.htm)
- 10-Q · filed 2026-05-06 · [filing](https://www.sec.gov/Archives/edgar/data/1384101/000138410126000031/0001384101-26-000031-index.htm)
- 8-K · filed 2026-05-05 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1384101/000138410126000029/0001384101-26-000029-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001384101.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1384101

## Cite

POPS4, Edgar & Edgarette: VERACYTE, INC. (VCYT) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/VCYT. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.